Skip to main content
Top
Published in: Breast Cancer Research 5/2010

Open Access 01-10-2010 | Research article

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

Authors: Isabel F Pinhel, Fiona A MacNeill, Margaret J Hills, Janine Salter, Simone Detre, Roger A'Hern, Ashutosh Nerurkar, Peter Osin, Ian E Smith, Mitch Dowsett

Published in: Breast Cancer Research | Issue 5/2010

Login to get access

Abstract

Introduction

Very few studies have investigated whether the time elapsed between surgical resection and tissue fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured biomarkers, including phosphorylated proteins in primary breast cancer. The aim of this study was to characterise the differences in immunoreactivity of common biomarkers that may occur (1) as a result of tissue handling at surgery and (2) between core-cuts and resected tumours.

Methods

Core-cuts taken from surgical breast cancer specimens immediately after resection (sample A) and after routine X-ray of the excised tumour (sample B) were formalin-fixed and paraffin-embedded and compared with the routinely fixed resection specimen (sample C). The variation in immunohistochemical expression of Ki67, oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2), p-Akt and p-Erk1/2 were investigated.

Results

Twenty-one tissue sets with adequate tumour were available. Median time between collection of core-cuts A and B was 30 minutes (range, 20 to 80 minutes). None of the markers showed significant differences between samples A and B. Similarly, Ki67, ER, PgR and HER2 did not differ significantly between core-cuts and main resection specimen, although there was a trend for lower resection values for ER (P = 0.06). However, p-Akt and p-Erk1/2 were markedly lower in resections than core-cuts (median, 27 versus 101 and 69 versus 193, respectively; both P < 0.0001 [two-sided]). This difference was significantly greater in mastectomy than in lumpectomy specimens for p-Erk1/2 (P = 0.01).

Conclusions

The delay in fixation in core-cuts taken after postoperative X-ray of resection specimens has no significant impact on expression of Ki67, ER, PgR, HER2, p-Akt or p-Erk1/2. However, extreme loss of phospho-staining can occur during routine fixation of resection specimens. These differences are likely attributable to suboptimal fixation and may have major repercussions for clinical research involving these markers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dowsett M: Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003, 9: 502s-PubMed Dowsett M: Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003, 9: 502s-PubMed
2.
go back to reference Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007, 25: 3816-3822. 10.1200/JCO.2006.09.6578.CrossRefPubMed Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007, 25: 3816-3822. 10.1200/JCO.2006.09.6578.CrossRefPubMed
3.
go back to reference Baker AF, Dragovich T, Ihle NT, William R, Fenoglio-Presiser C, Powis G: Stability of phosphoprotein as a biological marker of tumour signalling. Clin Cancer Res. 2005, 11: 4338-4340. 10.1158/1078-0432.CCR-05-0422.CrossRefPubMed Baker AF, Dragovich T, Ihle NT, William R, Fenoglio-Presiser C, Powis G: Stability of phosphoprotein as a biological marker of tumour signalling. Clin Cancer Res. 2005, 11: 4338-4340. 10.1158/1078-0432.CCR-05-0422.CrossRefPubMed
4.
go back to reference De Cecco L, Musella V, Veneroni S, Cappelletti V, Bongarzone I, Callari M, Valeri B, Pierotti MA, Daidone MG: Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer. 2009, 9: 409-10.1186/1471-2407-9-409.CrossRefPubMedPubMedCentral De Cecco L, Musella V, Veneroni S, Cappelletti V, Bongarzone I, Callari M, Valeri B, Pierotti MA, Daidone MG: Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer. 2009, 9: 409-10.1186/1471-2407-9-409.CrossRefPubMedPubMedCentral
5.
go back to reference Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LS, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol. 2007, 25: 118-145. 10.1200/JCO.2006.09.2775.CrossRefPubMed Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LS, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol. 2007, 25: 118-145. 10.1200/JCO.2006.09.2775.CrossRefPubMed
6.
go back to reference Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien MER, Scott T, Muchmore DB: Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev. 2001, 10: 961-966.PubMed Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien MER, Scott T, Muchmore DB: Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev. 2001, 10: 961-966.PubMed
7.
go back to reference Dowsett M, Dixon JM, Horgan K, Salter J, Hills M, Harvey E: Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res. 2000, 6: 2260-2267.PubMed Dowsett M, Dixon JM, Horgan K, Salter J, Hills M, Harvey E: Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res. 2000, 6: 2260-2267.PubMed
8.
go back to reference Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003, 120: 86-92. 10.1309/QPHDRB00QXGMUQ9N.CrossRefPubMed Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003, 120: 86-92. 10.1309/QPHDRB00QXGMUQ9N.CrossRefPubMed
9.
go back to reference Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M: Discordance between core needle biopsy (CBN) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009, 20: 1948-1952. 10.1093/annonc/mdp234.CrossRefPubMed Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M: Discordance between core needle biopsy (CBN) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009, 20: 1948-1952. 10.1093/annonc/mdp234.CrossRefPubMed
10.
go back to reference Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes J: Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score: results from TransATAC. Cancer Res. 2009, 69 (Suppl): 503s- Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes J: Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score: results from TransATAC. Cancer Res. 2009, 69 (Suppl): 503s-
11.
go back to reference Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005, 23: 2469-2476. 10.1200/JCO.2005.01.172.CrossRefPubMed Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005, 23: 2469-2476. 10.1200/JCO.2005.01.172.CrossRefPubMed
12.
go back to reference Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC, Landberg G: ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene. 2005, 24: 4370-4379. 10.1038/sj.onc.1208626.CrossRefPubMed Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC, Landberg G: ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene. 2005, 24: 4370-4379. 10.1038/sj.onc.1208626.CrossRefPubMed
13.
go back to reference Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE: Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009, 11: R11-10.1186/bcr2230.CrossRefPubMedPubMedCentral Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE: Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009, 11: R11-10.1186/bcr2230.CrossRefPubMedPubMedCentral
14.
go back to reference Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett J: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol. 2005, 207: 139-146. 10.1002/path.1829.CrossRefPubMed Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett J: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol. 2005, 207: 139-146. 10.1002/path.1829.CrossRefPubMed
15.
go back to reference Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD: Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest. 2005, 23: 483-487. 10.1080/07357900500201301.CrossRefPubMed Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD: Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest. 2005, 23: 483-487. 10.1080/07357900500201301.CrossRefPubMed
16.
go back to reference Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D: Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle. 2005, 4: 1369-1372.CrossRefPubMed Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D: Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle. 2005, 4: 1369-1372.CrossRefPubMed
17.
go back to reference Al-Bazz YO, Underwood JC, Brown BL, Dobson PR: Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer. 2009, 45: 694-704. 10.1016/j.ejca.2008.11.044.CrossRefPubMed Al-Bazz YO, Underwood JC, Brown BL, Dobson PR: Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer. 2009, 45: 694-704. 10.1016/j.ejca.2008.11.044.CrossRefPubMed
18.
go back to reference Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004, 96: 1133-1141. 10.1093/jnci/djh217.CrossRefPubMed Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004, 96: 1133-1141. 10.1093/jnci/djh217.CrossRefPubMed
19.
go back to reference Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005, 97: 880-887. 10.1093/jnci/dji161.CrossRefPubMed Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005, 97: 880-887. 10.1093/jnci/dji161.CrossRefPubMed
20.
go back to reference Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong JH, Wolmark N, Kidwell K, Paik S, Swain SM: Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol. 2010, 28: 2974-2981. 10.1200/JCO.2009.26.1602.CrossRefPubMedPubMedCentral Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong JH, Wolmark N, Kidwell K, Paik S, Swain SM: Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol. 2010, 28: 2974-2981. 10.1200/JCO.2009.26.1602.CrossRefPubMedPubMedCentral
Metadata
Title
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
Authors
Isabel F Pinhel
Fiona A MacNeill
Margaret J Hills
Janine Salter
Simone Detre
Roger A'Hern
Ashutosh Nerurkar
Peter Osin
Ian E Smith
Mitch Dowsett
Publication date
01-10-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2719

Other articles of this Issue 5/2010

Breast Cancer Research 5/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine